跳至主要内容
临床试验/NCT06157437
NCT06157437招募中不适用

An Exploratory Study of Focal Pulse Ablation System in the Treatment of Atrial Arrhythmia

Hangzhou Dinova EP Technology Co., Ltd1 个研究点 分布在 1 个国家目标入组 10 人开始时间: 2023年12月1日最近更新:

试验速览

阶段
不适用
状态
招募中
入组人数
10
试验地点
1
主要终点
Acute procedural success

研究概览

简要总结

This is a prospective, single-group clinical study. The objective is to evaluate the safety and efficacy of focal pulse ablation system in the treatment of typical atrial flutter.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Subjects aged at least 18;
  • Subjects with at least one typical atrial flutter attack recorded by ECG or holter in the 180 days prior to enrollment, and the ECG of other hospitals could be accepted;
  • Subjects are able to understand the purpose of the study, voluntarily participate in the study and sign the informed consent, and are willing to complete the follow-up according to the requirements of the program.

排除标准

  • Any prior cavo-tricuspid isthmus ablation;
  • Unstable angina;
  • Atrial flutter secondary to electrolyte disorder, thyroid disease or other reversible causes;
  • Myocardial infarction or coronary artery bypass grafting (CABG) or percutaneous coronary intervention (PCI) within the prior three months;
  • At baseline, New York College of Cardiology (NYHA) heart function grades III and IV;
  • Implantable devices such as ICDs, CRTS and pacemakers in the body;
  • Atrial or ventricular tumors, blood clots, thrombus, or known clotting disorders were recorded within the prior 90 days;
  • Severe structural heart disease, including tricuspid stenosis, tricuspid malformation, or other congenital heart disease that prevents ablation surgery;
  • Previously received tricuspid metal valve replacement;
  • Thromboembolic events (including transient ischemic attacks) within the past 6 months;
  • Mural thrombosis, tumor, or other abnormality that interferes with vascular puncture or catheter operation;
  • Severe lung disease, pulmonary hypertension or any lung disease involving abnormal blood gas or severe breathing difficulties;
  • Anticoagulation contraindications and a history of blood clotting or abnormal bleeding;
  • Acute systemic infection;
  • Serum creatinine greater than twice the upper limit of normal, or any history of renal dialysis;
  • Women who are pregnant or breastfeeding or who cannot use contraception during the study period;
  • Enrollment in another clinical trial evaluating other devices or drugs during the same period;
  • Life expectancy less than 12 months (e.g. advanced malignancy);
  • Abnormalities or diseases considered by the investigator to be excluded from inclusion in this study.

结局指标

主要结局

Acute procedural success

时间窗: immediately after the procedure

Acute procedural success is defined as the creation of bidirectional conduction block across the cavo-tricuspid isthmus immediately and 30 minutes after ablation.

次要结局

  • Ablation efficiency including total procedure time, catheter dwell time, pulse discharge time and total X-ray exposure time(immediately after the procedure)
  • Incidence of device-related severe adverse events (SAE)(3 months and 6 months after procedure)
  • Chronic success(6 months after procedure)
  • Incidence of device-related major adverse events (MAE) within 7 days after ablation(within 7 days after ablation)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验